Immuron (IMRN) Net Cash Flow (2016 - 2024)
Immuron's quarterly Net Cash Flow came in at -$2.6 million in Q4 2024, down 113.47% year-on-year from $19.3 million in Q1 2024, and down 113.47% quarter-over-quarter from -$1.2 million in Q4 2023.
Immuron has reported Net Cash Flow for 8 years, with the latest figure at -$2.6 million in Q4 2024.
- For the quarter ending Q4 2024, Net Cash Flow fell 113.47% year-over-year to -$2.6 million; the trailing twelve-month figure through Sep 2025 stood at -$2.6 million (down 113.47% YoY), and the FY2025 full-year result was -$8.8 million, down 59.19% from the prior year.
- Net Cash Flow for Q4 2024 stood at -$2.6 million, down from -$1.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $23.9 million in Q4 2020, with the low at -$2.6 million in Q4 2024.
- Average Net Cash Flow over 4 years is $5.0 million, with a median of -$608804.2 recorded in 2021.
- Year-over-year, Net Cash Flow soared 8005.28% in 2020 and tumbled 113.47% in 2024.
- Tracing IMRN's Net Cash Flow over 4 years: stood at $23.9 million in 2020, then sank by 99.99% to $2021.0 in 2021, then plunged by 60447.82% to -$1.2 million in 2023, then plunged by 113.47% to -$2.6 million in 2024.
- The last three Net Cash Flow figures came in at -$2.6 million (Q4 2024), -$1.2 million (Q4 2023), and $2021.0 (Q4 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.60 Mn |
| Dec 31, 2024 | -2.60 Mn |
| Dec 31, 2023 | -1.22 Mn |
| Dec 31, 2023 | -1.22 Mn |
| Dec 31, 2021 | 2,021.00 |
| Dec 31, 2021 | 2,021.00 |
| Dec 31, 2020 | 23.89 Mn |
| Dec 31, 2020 | 23.89 Mn |
| Dec 31, 2019 | -302,214.00 |
| Dec 31, 2019 | -302,214.00 |
| Dec 31, 2018 | -424,901.00 |
| Dec 31, 2018 | -424,901.00 |
| Dec 31, 2017 | -2.68 Mn |
| Dec 31, 2017 | -2.68 Mn |
| Dec 31, 2016 | 3.96 Mn |
| Dec 31, 2016 | 3.96 Mn |